Search PubMed⌕ Search

PubMed · 12583322

[Fibrinolysis modulators].

Abstract

The structure of fibrin network and the properties of the fibrinolytic enzymes (the formation, the efficiency of their activity and the rate of their inactivation) essentially determine the effectiveness of fibrinolysis. The fibrin structure and the action of proteases, however, depend considerably on additional physiological and pathological conditions. These are: cell membrane and components of endothelial cell, elastase of polymorphonuclear cells, actin and myosin in thrombus released by platelets and smooth muscle cells, certain denatured proteins, various immunoglobulins, some metabolites accumulated in diabetes mellitus, the inhibitor system of fibrinolytic enzymes (where and when proteases are available for inhibitors). In this survey, the biochemical basis makes understandable for the medical practitioner why urgent fibrinolytic therapy is required and why it would be ideal to initiate the formation of fibrinolytic enzymes at the site of thrombus.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Raymund Machovich. 2002-03-17. [Fibrinolysis modulators].. https://pubmed.ncbi.nlm.nih.gov/12583322/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Statins in heart failure. Beyond the lipid lowering effect.

Statins, the most widely prescribed medications in patients with hyperlipidemia and coronary heart disease, have a number of pleiotropic actions beyond cholesterol lowering. They improve endothelial function, they have antioxidant and anti-inflammatory effects, they regulate neovascularization and have immunomodulatory activities. Experimental evidence suggests that statins may be beneficial in heart failure as they can inhibit myocardial hypertrophy, reduce cardiomyocyte loss by apoptosis, reduce oxidative stress and restore neurohormonal imbalance. Furthermore small randomised clinical trials showed that short term statin administration may improve key pathophysiological aspects of this syndrome. Finally retrospective analyses of large statin trials imply a long term profit on clinical outcome in this group of patients. These results however need to be reviewed with caution as certain studies have demonstrated that low serum cholesterol is associated with worse prognosis in HF and that ubiquinone levels, a micronutrient with antioxidant actions, reduces significantly following statin administration. Large prospective randomised controlled trials are needed to confirm the beneficial effect of statins on cardiovascular outcome in HF patients and further elucidate the contributing mechanisms. Finally the statin dose and the interaction with co-administered drugs need to be studied.

Endothelium, Vascular↗